The Trial Will Assess The Safety And Effectiveness Of Various Formulations Of Cic And Flu Vaccine CandidatesNovavax Has Commenced A Phase Ii Trial For Its Covid-19-Influenza Combination (Cic) As Well As Influenza-Only Vaccine Candidates.The Randomised, Observer-Blinded, Dose-Confirming Trial Has Been Designed For Assessing The Effectiveness (Immunogenicity) And Safety Of Various Formulations Of The Cic And Influenza Vaccine Candidates In Participants Aged 50 To 80 Years.The Combination Of The Company
